On the public citation graph

Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?

0 signed · 54 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.ejca.2015.08.002openalex-snapshot
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials
inferredcites →https://doi.org/10.1016/s1470-2045(08)70003-2openalex-snapshot
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/s1470-2045(13)70093-7openalex-snapshot
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(13)70464-9openalex-snapshot
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
inferredcites →https://doi.org/10.1056/nejmoa1303989openalex-snapshot
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1080/02841860802314720openalex-snapshot
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
inferredcites →https://doi.org/10.1093/annonc/mdp025openalex-snapshot
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
inferredcites →https://doi.org/10.1093/annonc/mds179openalex-snapshot
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib
inferredcites →https://doi.org/10.1093/jnci/djq091openalex-snapshot
Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
inferredcites →https://doi.org/10.1093/jnci/djr128openalex-snapshot
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
inferredcites →https://doi.org/10.1093/jnci/djr328openalex-snapshot
Re: Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
inferredcites →https://doi.org/10.1097/00005344-199606000-00011openalex-snapshot
Effects of Vascular Endothelial Growth Factor on Hemodynamics and Cardiac Performance
inferredcites →https://doi.org/10.1097/00005344-200411000-00016openalex-snapshot
Vascular Endothelial Growth Factor-Induced Nitric Oxide- and PGI2-Dependent Relaxation in Human Internal Mammary Arteries
inferredcites →https://doi.org/10.1152/ajpheart.1998.274.3.h1054openalex-snapshot
VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
inferredcites →https://doi.org/10.1158/1078-0432.ccr-10-2806openalex-snapshot
Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
inferredcites →https://doi.org/10.1161/01.atv.17.11.2793openalex-snapshot
Vascular Endothelial Growth Factor/Vascular Permeability Factor Produces Nitric Oxide–Dependent Hypotension
inferredcites →https://doi.org/10.1161/01.hyp.0000167992.80876.26openalex-snapshot
Vascular Development, Pulse Pressure, and the Mechanisms of Hypertension
inferredcites →https://doi.org/10.1161/circoutcomes.110.957951openalex-snapshot
Landmark Analysis at the 25-Year Landmark Point
inferredcites →https://doi.org/10.1161/hypertensionaha.110.160481openalex-snapshot
Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors
inferredcites →https://doi.org/10.1200/jco.1983.1.11.710openalex-snapshot
Analysis of survival by tumor response.
inferredcites →https://doi.org/10.1200/jco.1986.4.1.115openalex-snapshot
Analysis of survival by tumor response.
inferredcites →https://doi.org/10.1200/jco.2008.21.6994openalex-snapshot
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
inferredcites →https://doi.org/10.1200/jco.2009.23.9764openalex-snapshot
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
inferredcites →https://doi.org/10.1634/theoncologist.2012-0339openalex-snapshot
Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III Studies
inferredcites →https://doi.org/10.3109/02841860903524396openalex-snapshot
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4788499openalex-extracted
Integrated Analysis of VEGF and VEGFR Inhibitor-Induced Hypertension: Insights from Pharmacovigilance, Clinical Data, and Animal Models
inferred← citeshttps://doi.org/10.2139/ssrn.4804332openalex-extracted
Integrated Analysis of VEGF and VEGFR Inhibitor-Induced Hypertension: Insights from Pharmacovigilance, Clinical Data, and Animal Models
inferred← citeshttps://doi.org/10.1007/s10637-021-01138-xopenalex-snapshot
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors
inferred← citeshttps://doi.org/10.1007/s12012-025-09980-8openalex-snapshot
Apatinib-Induced Hypertension Correlates with Improved Prognosis in Solid Tumor Patients
inferred← citeshttps://doi.org/10.1007/s40262-017-0510-zopenalex-snapshot
Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
inferred← citeshttps://doi.org/10.1016/j.clgc.2016.10.004openalex-snapshot
Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib
inferred← citeshttps://doi.org/10.1016/j.clgc.2019.03.012openalex-snapshot
Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution
inferred← citeshttps://doi.org/10.1016/j.euros.2020.11.003openalex-snapshot
Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not
inferred← citeshttps://doi.org/10.1038/s41392-019-0049-6openalex-snapshot
Pazopanib in advanced soft tissue sarcomas
inferred← citeshttps://doi.org/10.1080/07357907.2017.1292518openalex-snapshot
Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study
inferred← citeshttps://doi.org/10.1080/14737140.2017.1269605openalex-snapshot
On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?
inferred← citeshttps://doi.org/10.1089/ten.teb.2015.0300openalex-snapshot
Repositioning Bevacizumab: A Promising Therapeutic Strategy for Cartilage Regeneration
inferred← citeshttps://doi.org/10.1093/jjco/hyy053openalex-snapshot
Drug review: Pazopanib
inferred← citeshttps://doi.org/10.1097/fpc.0000000000000292openalex-snapshot
PharmGKB summary
inferred← citeshttps://doi.org/10.1097/hjh.0000000000002006openalex-snapshot
Arterial hypertension in patients under antineoplastic therapy
inferred← citeshttps://doi.org/10.1177/1758834018755090openalex-snapshot
Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study
inferred← citeshttps://doi.org/10.1186/s12894-019-0481-5openalex-snapshot
Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1186/s40360-018-0264-8openalex-snapshot
Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
inferred← citeshttps://doi.org/10.1186/s40880-017-0263-yopenalex-snapshot
Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
inferred← citeshttps://doi.org/10.1186/s40959-021-00101-2openalex-snapshot
Etiology and management of hypertension in patients with cancer
inferred← citeshttps://doi.org/10.1253/circrep.cr-26-0054openalex-snapshot
Late-Onset Hypertension Is Associated With Improved Clinical Outcomes in Cancer Patients Treated With Sunitinib
inferred← citeshttps://doi.org/10.2174/1570161117666190130165810openalex-snapshot
Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment
inferred← citeshttps://doi.org/10.26442/18151434.2023.2.202262openalex-snapshot
Safety and toxicity of cabozantinib monotherapy in patients with advanced renal cell carcinoma: a Russian multicenter observational study
inferred← citeshttps://doi.org/10.3238/arztebl.2019.0775openalex-snapshot
New Oral Anti-Cancer Drugs and Medication Safety
inferred← citeshttps://doi.org/10.32604/cju.2025.063073openalex-snapshot
Differences at diagnosis between long-term survivors and not long-term survivors in metastatic renal cell carcinoma initially treated with TKI
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1488853openalex-snapshot
Comprehensive analysis of VEGF/VEGFR inhibitor-induced immune-mediated hypertension: integrating pharmacovigilance, clinical data, and preclinical models
inferred← citeshttps://doi.org/10.3390/ijms17122073openalex-snapshot
Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
inferred← citeshttps://doi.org/10.3892/ol.2021.12576openalex-snapshot
Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs (Review)
inferred← citeshttps://doi.org/10.5301/jo-n.5000013openalex-snapshot
Hypertension and Survival in Renal Cell Carcinoma Treated with anti-VEGFR Agents: A Systematic Review and Meta-Analysis
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.